» Articles » PMID: 20069274

Procalcitonin and C-reactive Protein in Severe 2009 H1N1 Influenza Infection

Overview
Specialty Critical Care
Date 2010 Jan 14
PMID 20069274
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To examine whether, in an adult intensive care unit (ICU), procalcitonin or C-reactive protein (CRP) levels discriminated between 2009 H1N1 influenza infection and community-acquired pneumonia of bacterial origin.

Methods: A retrospective observational study performed at an Australian hospital over a 4-month winter period during the 2009 H1N1 influenza pandemic. Levels on admission of procalcitonin and CRP were compared between patients admitted to the ICU with community-acquired pneumonia of bacterial and 2009 H1N1 origin.

Results: Compared to those with bacterial or mixed infection (n = 9), patients with 2009 H1N1 infection (n = 16) were significantly more likely to have bilateral chest X-ray infiltrates, lower APACHE scores, more prolonged lengths of stay in ICU and lower white cell count, procalcitonin and CRP levels. Using a cutoff of >0.8 ng/ml, the sensitivity and specificity of procalcitonin for detection of patients with bacterial/mixed infection were 100 and 62%, respectively. A CRP cutoff of >200 mg/l best identified patients with bacterial/mixed infection (sensitivity 100%, specificity 87.5%). In combination, procalcitonin levels >0.8 ng/ml and CRP >200 mg/l had optimal sensitivity (100%), specificity (94%), negative predictive value (100%) and positive predictive value (90%). Receiver-operating characteristic curve analysis suggested the diagnostic accuracy of procalcitonin may be inferior to CRP in this setting.

Conclusions: Procalcitonin measurement potentially assists in the discrimination between severe lower respiratory tract infections of bacterial and 2009 H1N1 origin, although less effectively than CRP. Low values, particularly when combined with low CRP levels, suggested bacterial infection, alone or in combination with influenza, was unlikely.

Citing Articles

Influenza and Aging: Clinical Manifestations, Complications, and Treatment Approaches in Older Adults.

Rosero C, Gravenstein S, Saade E Drugs Aging. 2025; 42(1):39-55.

PMID: 39775605 DOI: 10.1007/s40266-024-01169-y.


Latest developments in early diagnosis and specific treatment of severe influenza infection.

Valenzuela-Sanchez F, Valenzuela-Mendez B, Rodriguez-Gutierrez J, Estella A J Intensive Med. 2024; 4(2):160-174.

PMID: 38681787 PMC: 11043645. DOI: 10.1016/j.jointm.2023.09.006.


Plasma levels of neurogenic inflammation related neuropeptides in pediatric patients with community-acquired pneumonia and their potential diagnostic value in distinguishing viral and bacterial pneumonia.

Bekdas M, Saygi B, Baranoglu Kilinc Y, Kilinc E Eur J Pediatr. 2024; 183(4):1619-1627.

PMID: 38183438 PMC: 11001734. DOI: 10.1007/s00431-023-05417-y.


Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients.

Galli F, Bindo F, Motos A, Fernandez-Barat L, Barbeta E, Gabarrus A Intensive Care Med. 2023; 49(8):934-945.

PMID: 37507573 PMC: 10425511. DOI: 10.1007/s00134-023-07161-1.


Electrochemical Label-free Methods for Ultrasensitive Multiplex Protein Profiling of Infectious Diseases.

Madhurantakam S, Churcher N, Kumar R, Prasad S Curr Med Chem. 2023; 31(25):3857-3869.

PMID: 37303174 DOI: 10.2174/0929867330666230609112052.


References
1.
Baskin C, Bielefeldt-Ohmann H, Tumpey T, Sabourin P, Long J, Garcia-Sastre A . Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A. 2009; 106(9):3455-60. PMC: 2642661. DOI: 10.1073/pnas.0813234106. View

2.
Masia M, Gutierrez F, Shum C, Padilla S, Navarro J, Flores E . Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest. 2005; 128(4):2223-9. DOI: 10.1378/chest.128.4.2223. View

3.
Niederman M . Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis. 2008; 47 Suppl 3:S127-32. DOI: 10.1086/591393. View

4.
Christ-Crain M, Muller B . Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007; 30(3):556-73. DOI: 10.1183/09031936.00166106. View

5.
Webb S, Pettila V, Seppelt I, Bellomo R, Bailey M, Cooper D . Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009; 361(20):1925-34. DOI: 10.1056/NEJMoa0908481. View